These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34188467)

  • 41. Clinical recommendations for dry powder inhaler use in the management of COPD in primary care.
    Leving MT; Bosnic-Anticevich S; van Cooten J; de Sousa JC; Cvetkovski B; Dekhuijzen R; Dijk L; Pardo MG; Gardev A; Gawlik R; van der Ham I; Janse Y; Lavorini F; Maricoto T; Meijer J; Metz B; Price D; Roman-Rodriguez M; Schuttel K; Stoker N; Tsiligianni I; Usmani O; Emerson-Stadler R; Kocks JWH
    NPJ Prim Care Respir Med; 2022 Dec; 32(1):59. PubMed ID: 36575175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study.
    Zervas E; Samitas K; Gaga M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1845-55. PubMed ID: 27540287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease.
    Mahler DA
    Ann Am Thorac Soc; 2017 Jul; 14(7):1103-1107. PubMed ID: 28481631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data.
    Anderson M; Collison K; Drummond MB; Hamilton M; Jain R; Martin N; Mularski RA; Thomas M; Zhu CQ; Ferguson GT
    Int J Chron Obstruct Pulmon Dis; 2021; 16():933-943. PubMed ID: 33883890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study.
    Virchow JC; Weuthen T; Harmer QJ; Jones S
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1849-57. PubMed ID: 25151851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison.
    Broeders ME; Molema J; Burnell PK; Folgering HT
    J Aerosol Med; 2005; 18(1):74-82. PubMed ID: 15741776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
    Grant AC; Walker R; Hamilton M; Garrill K
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Getting the Most out of Spirometry: A Tool to Guide Dry Powder Inhaler Use.
    Hanon S; Vanderhelst E; Buls N; Verbanck S
    Respiration; 2022; 101(10):893-900. PubMed ID: 36030775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions.
    Loh CH; Peters SP; Lovings TM; Ohar JA
    Ann Am Thorac Soc; 2017 Aug; 14(8):1305-1311. PubMed ID: 28406710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers.
    Broeders ME; Molema J; Vermue NA; Folgering HT
    Eur Respir J; 2001 Nov; 18(5):780-3. PubMed ID: 11757627
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship.
    Kanabuchi K; Kondo T; Tanigaki T; Tajiri S; Hayama N; Takahari Y; Iwao K
    Tokai J Exp Clin Med; 2011 Apr; 36(1):1-4. PubMed ID: 21547884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD.
    van der Palen J; Moeskops-van Beurden W; Dawson CM; James WY; Preece A; Midwinter D; Barnes N; Sharma R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2515-2523. PubMed ID: 30174421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An evaluation of the use of inhalers in asthma and chronic obstructive pulmonary disease.
    Çakmaklı S; Özdemir A; Fırat H; Aypak C
    J Taibah Univ Med Sci; 2023 Aug; 18(4):860-867. PubMed ID: 36852239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study.
    Ramadan WH; Sarkis AT
    Chron Respir Dis; 2017 Aug; 14(3):309-320. PubMed ID: 28774201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurement of inspiratory flow in children with acute asthma.
    Bentur L; Mansour Y; Hamzani Y; Beck R; Elias N; Amirav I
    Pediatr Pulmonol; 2004 Oct; 38(4):304-7. PubMed ID: 15334507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inappropriate Peak Inspiratory Flow Rate with Dry Powder Inhaler in Chronic Obstructive Pulmonary Disease.
    Chen SY; Huang CK; Peng HC; Yu CJ; Chien JY
    Sci Rep; 2020 Apr; 10(1):7271. PubMed ID: 32350352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.